LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

LLY

836.99

-0.74%↓

UNH

515.83

+1.16%↑

JNJ

163.37

+0.29%↑

ABBV

209.84

-0.76%↓

NVO

76.76

-2.48%↓

Search

Capricor Therapeutics Inc

Cerrado

12.75 -10.84

Resumen

Variación precio

24h

Actual

Mínimo

12.75

Máximo

13.09

Métricas clave

By Trading Economics

Ingresos

-1.6M

-13M

Ventas

-1.7M

2.3M

BPA

-0.38

Margen de beneficio

-555.204

Empleados

101

EBITDA

-1.4M

-13M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+239.04% upside

Dividendos

By Dow Jones

Próximas Ganancias

12 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

586M

Apertura anterior

23.59

Cierre anterior

12.75

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Capricor Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 mar 2025, 15:41 UTC

Principales Movimientos del Mercado

Capricor Therapeutics Shares Rise on FDA Priority Review

Comparación entre iguales

Cambio de precio

Capricor Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

239.04% repunte

Estimación a 12 meses

Media 43.6 USD  239.04%

Máximo 77 USD

Mínimo 25 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Capricor Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

12.81 / 13.4235Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.